INMB Q3 2018 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$38M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-0.14

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$449,929

Free Cash Flow

-$449,929

Stock-Based Comp.

$979,556

Balance Sheet

Total Assets

$18M

Total Liabilities

$211,431

Stockholders' Equity

$17M

Cash & Equivalents

$650,861

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$308,000	-400.0%
Net Income	-$2M	-$308,000	-400.0%